Nuveen LLC Takes Position in Y-mAbs Therapeutics, Inc. $YMAB

Key Points

• Nuveen LLC has acquired 112,483 shares of Y-mAbs Therapeutics, valued at approximately $498,000, representing about 0.25% ownership of the company.
• Several analysts have downgraded Y-mAbs Therapeutics' stock ratings to "hold" and set the price target at $8.60, reflecting a significant decrease from previous estimates.
• The company reported a positive EPS of ($0.07), exceeding analyst expectations, with quarterly revenue of $19.52 million against estimates of $18.40 million.

Nuveen LLC acquired a new position in shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report) during the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 112,483 shares of the company's stock, valued at approximately $498,000. Nuveen LLC owned approximately 0.25% of Y-mAbs Therapeutics at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Connor Clark & Lunn Investment Management Ltd. bought a new stake in Y-mAbs Therapeutics in the first quarter worth $49,000. Corton Capital Inc. bought a new stake in shares of Y-mAbs Therapeutics in the 1st quarter worth about $55,000. ProShare Advisors LLC purchased a new position in shares of Y-mAbs Therapeutics during the 4th quarter worth about $99,000. Wells Fargo & Company MN grew its holdings in Y-mAbs Therapeutics by 54.1% during the 4th quarter. Wells Fargo & Company MN now owns 17,458 shares of the company's stock valued at $137,000 after purchasing an additional 6,131 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Y-mAbs Therapeutics by 12.6% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,818 shares of the company's stock worth $179,000 after purchasing an additional 2,545 shares during the period. 70.85% of the stock is owned by hedge funds and other institutional investors.

Y-mAbs Therapeutics Stock Performance

Shares of YMAB stock remained flat at $8.58 on Wednesday. The company had a trading volume of 655,258 shares, compared to its average volume of 911,612. Y-mAbs Therapeutics, Inc. has a 12-month low of $3.55 and a 12-month high of $16.11. The business has a 50 day moving average price of $6.67 and a 200 day moving average price of $5.34. The company has a market capitalization of $389.88 million, a P/E ratio of -17.16 and a beta of 0.54.

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) last posted its earnings results on Friday, August 8th. The company reported ($0.07) EPS for the quarter, beating analysts' consensus estimates of ($0.27) by $0.20. Y-mAbs Therapeutics had a negative net margin of 26.03% and a negative return on equity of 24.60%. The business had revenue of $19.52 million for the quarter, compared to the consensus estimate of $18.40 million. On average, research analysts predict that Y-mAbs Therapeutics, Inc. will post -0.65 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on YMAB. Brookline Capital Management lowered Y-mAbs Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, August 5th. Morgan Stanley set a $8.60 price objective on Y-mAbs Therapeutics in a report on Tuesday, August 5th. Oppenheimer downgraded Y-mAbs Therapeutics from an "outperform" rating to a "market perform" rating in a research report on Tuesday, August 5th. Truist Financial set a $8.60 price target on shares of Y-mAbs Therapeutics in a report on Tuesday, August 5th. Finally, Jones Trading downgraded shares of Y-mAbs Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, August 5th. Eight research analysts have rated the stock with a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, Y-mAbs Therapeutics currently has a consensus rating of "Reduce" and an average price target of $9.62.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.